B. C. Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 0.40 M
- Revenue Growth %
- Profit Growth 81.98%
- Ebitda 133.33%
- Net Worth -4.01%
- Total Assets -3.78%
About B. C. Pharmaceuticals
B. C. Pharmaceuticals Private Limited (BCPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 October 2018 (Six years and three months 10 days old ). Its registered office is in Varanasi, Uttar Pradesh, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.40 M.
Rahul Moulick, Rohit Moulick, and Tushar Sinha serve as directors at the Company.
Company Details
-
Location
Varanasi, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51900UP2018PTC109946
-
Company No.
109946
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Oct 2018
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at B. C. Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Moulick
|
Director | 31-Oct-2018 | Current |
|
Rohit Moulick
|
Director | 31-Oct-2018 | Current |
|
Tushar Sinha
|
Director | 31-Oct-2018 | Current |
Financial Performance of B. C. Pharmaceuticals.
B. C. Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 81.98% increase in profit. The company's net worth dipped by a decrease of 4.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of B. C. Pharmaceuticals?
Unlock access to B. C. Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.40 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.04 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Nov 2020 | Others | ₹0.40 M | Open |
How Many Employees Work at B. C. Pharmaceuticals?
Unlock and access historical data on people associated with B. C. Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of B. C. Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped B. C. Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.